Verve Therapeutics Analyst Ratings
Verve Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/13/2023 | 64.67% | Cantor Fitzgerald | → $22 | Reiterates | Neutral → Neutral |
| 08/29/2023 | 64.67% | Cantor Fitzgerald | → $22 | Reiterates | Neutral → Neutral |
| 08/15/2023 | 311.68% | Guggenheim | $56 → $55 | Maintains | Buy |
| 08/11/2023 | 132.04% | Credit Suisse | → $31 | Reiterates | Neutral → Neutral |
| 06/16/2023 | 117.07% | Canaccord Genuity | → $29 | Reiterates | Buy → Buy |
| 05/16/2023 | 161.98% | RBC Capital | → $35 | Reiterates | Outperform → Outperform |
| 04/13/2023 | 117.07% | Canaccord Genuity | → $29 | Initiates Coverage On | → Buy |
| 02/01/2023 | 57.19% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Neutral |
| 12/15/2022 | -2.69% | Goldman Sachs | → $13 | Initiates Coverage On | → Sell |
| 11/08/2022 | 161.98% | RBC Capital | $42 → $35 | Maintains | Outperform |
| 10/06/2022 | 259.28% | Credit Suisse | → $48 | Initiates Coverage On | → Neutral |
| 08/25/2022 | 319.16% | Stifel | $32 → $56 | Upgrades | Hold → Buy |
| 07/18/2022 | 364.07% | BMO Capital | $48 → $62 | Maintains | Outperform |
| 06/17/2022 | 259.28% | BMO Capital | → $48 | Initiates Coverage On | → Outperform |
| 02/18/2022 | 214.37% | RBC Capital | → $42 | Initiates Coverage On | → Outperform |
| 09/24/2021 | 334.13% | Stifel | → $58 | Initiates Coverage On | → Hold |
| 07/12/2021 | 588.62% | William Blair | → $92 | Initiates Coverage On | → Outperform |
| 07/12/2021 | 528.74% | Guggenheim | → $84 | Initiates Coverage On | → Buy |
| 07/12/2021 | 274.25% | JP Morgan | → $50 | Initiates Coverage On | → Neutral |
| 07/12/2021 | — | Jefferies | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/13/2023 | 64.67% | 康托·菲茨杰拉德 | →$22 | 重申 | 中性→中性 |
| 2023年08月29日 | 64.67% | 康托·菲茨杰拉德 | →$22 | 重申 | 中性→中性 |
| 2023年08月15日 | 311.68% | 古根海姆 | $56→$55 | 维护 | 买 |
| 2023年08月11日 | 132.04% | 瑞士信贷 | →$31 | 重申 | 中性→中性 |
| 06/16/2023 | 117.07% | 卡纳科特·格纳奇 | →$29 | 重申 | 购买→购买 |
| 2023年05月16日 | 161.98% | 加拿大皇家银行资本 | →$35 | 重申 | 跑赢→跑赢大盘 |
| 04/13/2023 | 117.07% | 卡纳科特·格纳奇 | →$29 | 开始承保 | →购买 |
| 02/01/2023 | 57.19% | 康托·菲茨杰拉德 | →$21 | 开始承保 | →中性 |
| 2022年12月15日 | -2.69% | 高盛 | →$13 | 开始承保 | →销售 |
| 11/08/2022 | 161.98% | 加拿大皇家银行资本 | $42→$35 | 维护 | 跑赢大盘 |
| 10/06/2022 | 259.28% | 瑞士信贷 | →$48 | 开始承保 | →中性 |
| 2022年08月25日 | 319.16% | Stifel | $32→$56 | 升级 | 持有→购买 |
| 07/18/2022 | 364.07% | 蒙特利尔银行资本 | $48→$62 | 维护 | 跑赢大盘 |
| 06/17/2022 | 259.28% | 蒙特利尔银行资本 | →$48 | 开始承保 | →跑赢大盘 |
| 02/18/2022 | 214.37% | 加拿大皇家银行资本 | →$42 | 开始承保 | →跑赢大盘 |
| 09/24/2021 | 334.13% | Stifel | →$58 | 开始承保 | →保留 |
| 07/12/2021 | 588.62% | 威廉·布莱尔 | →$92 | 开始承保 | →跑赢大盘 |
| 07/12/2021 | 528.74% | 古根海姆 | →$84 | 开始承保 | →购买 |
| 07/12/2021 | 274.25% | 摩根大通 | →$50 | 开始承保 | →中性 |
| 07/12/2021 | - | 杰富瑞 | 开始承保 | →购买 |
What is the target price for Verve Therapeutics (VERV)?
Verve Treateutics(VERV)的目标价格是多少？
The latest price target for Verve Therapeutics (NASDAQ: VERV) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $22.00 expecting VERV to rise to within 12 months (a possible 64.67% upside). 11 analyst firms have reported ratings in the last year.
康托·菲茨杰拉德于2023年9月13日报道了Verve治疗公司(纳斯达克：VERV)的最新目标价。这家分析公司将目标价定为22.00美元，预计VERV将在12个月内升至(可能上涨64.67%)。过去一年，有11家分析公司公布了评级。
What is the most recent analyst rating for Verve Therapeutics (VERV)?
Verve Treateutics(VERV)的最新分析师评级是什么？
The latest analyst rating for Verve Therapeutics (NASDAQ: VERV) was provided by Cantor Fitzgerald, and Verve Therapeutics reiterated their neutral rating.
对Verve治疗公司(纳斯达克代码：VERV)的最新分析师评级是由坎托·菲茨杰拉德提供的，Verve治疗公司重申了他们的中性评级。
When is the next analyst rating going to be posted or updated for Verve Therapeutics (VERV)?
Verve治疗公司(VERV)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verve Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verve Therapeutics was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Verve Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Verve治疗公司的上一次评级是在2023年9月13日提交的，所以你应该预计下一次评级将在2024年9月13日左右的某个时候提供。
Is the Analyst Rating Verve Therapeutics (VERV) correct?
分析师对Verve Treateutics(VERV)的评级正确吗？
While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a reiterated with a price target of $0.00 to $22.00. The current price Verve Therapeutics (VERV) is trading at is $13.36, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Verve治疗(VERV)评级被重申，目标价在0.00美元至22.00美元之间。Verve Treateutics(VERV)目前的交易价格为13.36美元，在分析师的预测范围内。